DOT1L regulates dystrophin expression and is critical for cardiac function

Genes and Development

Volumn 25, Issue 3, 2011, Pages 263-274

  Nguyen, Anh T ^a,b   Xiao, Bin ^a   Neppl, Ronald L ^c   Kallin, Eric M ^a,b,e   Li, Juan ^a   Chen, Taiping ^d   Wang, Da Zhi ^c   Xiao, Xiao ^a   Zhang, Yi ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

Cardiomyopathy; DOT1L; Dystrophin; H3K79 methylation

Indexed keywords

DYSTROPHIN; GLYCOPROTEIN; METHYLTRANSFERASE; PROTEIN DOT1L; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; HEART FUNCTION; HEART MUSCLE CELL; HISTONE METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOMEGALY; CELL LINE; DOWN-REGULATION; DYSTROPHIN; HUMANS; METHYLTRANSFERASES; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC;

MAMMALIA; MUS;

EID: 79551607266     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.2018511     Document Type: Article

References (73)

1. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, et al. 1999. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104: 1703-1714.
2. Ahuja P, Sdek P, MacLellan WR. 2007. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 87: 521-544.
3. Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. 2007. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293: H1883-H1891. doi: 10.1152/ajpheart.00514.2007.
4. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. 2002. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 160: 2035-2043.
5. Barry ER, Krueger W, Jakuba CM, Veilleux E, Ambrosi DJ, Nelson CE, Rasmussen TP. 2009. ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L. Stem Cells 27: 1538-1547.
6. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
7. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kaab S, Kreuzer E, Steinbeck G, Mansmann U, et al. 2006. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol 48: 1610-1617.
8. Camargo A, Azuaje F. 2008. Identification of dilated cardiomyopathy signature genes through gene expression and network data integration. Genomics 92: 404-413.
9. Cao R, Wang H, He J, Erdjument-Bromage H, Tempst P, Zhang Y. 2008. Role of hPHF1 in H3K27 methylation and Hox gene silencing. Mol Cell Biol 28: 1862-1872.
10. Cohn JN, Ferrari R, Sharpe N. 2000. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569-582.
11. Conde F, Refolio E, Cordon-Preciado V, Cortes-Ledesma F, Aragon L, Aguilera A, San-Segundo PA. 2009. The Dot1 histone methyltransferase and the Rad9 checkpoint adaptor contribute to cohesin-dependent double-strand break repair by sister chromatid recombination in Saccharomyces cerevisiae. Genetics 182: 437-446.
12. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, et al. 2008. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 155: 998-1005.
13. Dahl JA, Collas P. 2008. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 3: 1032-1045.
14. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. 1997. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727.
15. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ, Galama JM. 2001. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int 14: 299-306.
16. Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, Erdjument- Bromage H, Tempst P, Simon JA, Zhang Y. 2002. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol 12: 1086-1099.
17. Feinberg AP, Oshimura M, Barrett JC. 2002. Epigenetic mechanisms in human disease. Cancer Res 62: 6784-6787.
18. Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, Zhang Y. 2002. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12: 1052-1058.
19. Feng Y, Yang Y, Ortega MM, Copeland JN, Zhang M, Jacob JB, Fields TA, Vivian JL, Fields PE. 2010. Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood 116: 4483-4491.
20. Galvagni F, Lestingi M, Cartocci E, Oliviero S. 1997. Serum response factor and protein-mediated DNA bending contribute to transcription of the dystrophin muscle-specific promoter. Mol Cell Biol 17: 1731-1743.
21. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitas K, Sasse-Klaassen S, Seidman JG, Seidman C, Granzier H, Labeit S, et al. 2002. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30: 201-204.
22. Giannattasio M, Lazzaro F, Plevani P, Muzi-Falconi M. 2005. The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1. J Biol Chem 280: 9879-9886.
23. Gotthardt M, Hammer RE, Hubner N, Monti J, Witt CC, McNabb M, Richardson JA, Granzier H, Labeit S, Herz J. 2003. Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure. J Biol Chem 278: 6059-6065.
24. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. 1997. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 90: 729-738.
25. Ha CH, Kim JY, Zhao J, Wang W, Jhun BS, Wong C, Jin ZG. 2010. PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci 107: 15467-15472.
26. Handel AE, Ebers GC, Ramagopalan SV. 2009. Epigenetics: Molecular mechanisms and implications for disease. Trends Mol Med 16: 7-16.
27. Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, Zhou B, Chang CP. 2010. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466: 62-67.
28. Hatcher CJ, Basson CT. 2009. Specification of the cardiac conduction system by transcription factors. Circ Res 105: 620-630.
29. He J, Kallin EM, Tsukada Y, Zhang Y. 2008. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nat Struct Mol Biol 15: 1169-1175.
30. Heydemann A, McNally EM. 2007. Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc Med 17: 55-59.
31. Hoffman EP, Brown RH Jr, Kunkel LM. 1987. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
32. Houweling AC, van Borren MM, Moorman AF, Christoffels VM. 2005. Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. Cardiovasc Res 67: 583-593.
33. Jones B, Su H, Bhat A, Lei H, Bajko J, Hevi S, Baltus GA, Kadam S, Zhai H, Valdez R, et al. 2008. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 4: e1000190. doi: 10.1371/journal.pgen.1000190.
34. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. 1998. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci 95: 8801-8805.
35. Kaneda R, Takada S, Yamashita Y, Choi YL, Nonaka-Sarukawa M, Soda M, Misawa Y, Isomura T, Shimada K, Mano H. 2009. Genome-wide histone methylation profile for heart failure. Genes Cells 14: 69-77.
36. Karkkainen S, Peuhkurinen K. 2007. Genetics of dilated cardiomyopathy. Ann Med 39: 91-107.
37. Kimura, A. 2008. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 72: A38-A48.
38. Knaapen MW, Davies MJ, De Bie M, Haven AJ, Martinet W, Kockx MM. 2001. Apoptotic versus autophagic cell death in heart failure. Cardiovasc Res 51: 304-312.
39. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA. 2003. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112: 863-871.
40. Kostin S, Hein S, Arnon E, Scholz D, Schaper J. 2000. The cytoskeleton and related proteins in the human failing heart. Heart Fail Rev 5: 271-280.
41. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
42. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, et al. 2008. H3K79 methylation profiles define murine and human MLLAF4 leukemias. Cancer Cell 14: 355-368.
43. Krogan NJ, Dover J, Wood A, Schneider J, Heidt J, Boateng MA, Dean K, Ryan OW, Golshani A, Johnston M, et al. 2003. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: Linking transcriptional elongation to histone methylation. Mol Cell 11: 721-729.
44. Lacoste N, Utley RT, Hunter JM, Poirier GG, Cote J. 2002. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J Biol Chem 277: 30421-30424.
45. Liew CC, Dzau VJ. 2004. Molecular genetics and genomics of heart failure. Nat Rev Genet 5: 811-825.
46. Luk A, Ahn E, Soor GS, Butany J. 2009. Dilated cardiomyopathy: A review. J Clin Pathol 62: 219-225.
47. Martin C, Zhang Y. 2005. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 6: 838-849.
48. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, Washburn MP, Florens L, Shilatifard A. 2010. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24: 574-589.
49. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. 2007. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21: 1790-1802.
50. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS. 2010. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS ONE 5: e8564. doi: 10.1371/journal.pone. 0008564.
51. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, et al. 2007. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110: 4445-4454.
52. Ng HH, Feng Q, Wang H, Erdjument-Bromage H, Tempst P, Zhang Y, Struhl K. 2002a. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev 16: 1518-1527.
53. Ng HH, Xu RM, Zhang Y, Struhl K. 2002b. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem 277: 34655-34657.
54. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y. 2005. hDOT1L links histone methylation to leukemogenesis. Cell 121: 167-178.
55. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. 2006. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 8: 1017-1024.
56. Olson EN. 2004. A decade of discoveries in cardiac biology. Nat Med 10: 467-474.
57. Peterson CL, Laniel MA. 2004. Histones and histone modifications. Curr Biol 14: R546-R551. doi: 10.1016/j.cub.2004.07.007.
58. San-Segundo PA, Roeder GS. 2000. Role for the silencing protein Dot1 in meiotic checkpoint control. Mol Biol Cell 11: 3601-3615.
59. Schubeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F, Gottschling DE, O'Neill LP, Turner BM, Delrow J, et al. 2004. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18: 1263-1271.
60. Seidman JG, Seidman C. 2001. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 104: 557-567.
61. Singer MS, Kahana A, Wolf AJ, Meisinger LL, Peterson SE, Goggin C, Mahowald M, Gottschling DE. 1998. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 150: 613-632.
62. Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, Vakoc AL, Kim JE, Chen J, Lazar MA, et al. 2008. DOT1L/ KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 28: 2825-2839.
63. Towbin JA, Bowles NE. 2006. Dilated cardiomyopathy: A tale of cytoskeletal proteins and beyond. J Cardiovasc Electrophysiol 17: 919-926.
64. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. 2008. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16: 832-835.
65. van Leeuwen F, Gafken PR, Gottschling DE. 2002. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 109: 745-756.
66. Wang B, Li J, Xiao X. 2000. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci 97: 13714-13719.
67. Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, Jiang X, Xiao X. 2008. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 15: 1489-1499.
68. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, et al. 2008. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40: 897-903.
69. Weinert S, Bergmann N, Luo X, Erdmann B, Gotthardt M. 2006. M line-deficient titin causes cardiac lethality through impaired maturation of the sarcomere. J Cell Biol 173: 559-570.
70. Wood A, Schneider J, Dover J, Johnston M, Shilatifard A. 2003. The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p. J Biol Chem 278: 34739-34742.
71. Wysocki R, Javaheri A, Allard S, Sha F, Cote J, Kron SJ. 2005. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol 25: 8430-8443.
72. Xiao X, Li J, Samulski RJ. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
73. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. 2002. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488.